How does ketamine elicit a rapid antidepressant response?

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

A single sub-psychotomimetic dose of ketamine, an ionotropic glutamatergic n-methyl-D-aspartate (NMDA) receptor antagonist, produces a fast-acting antidepressant response in patients suffering from major depressive disorder. Depressed patients report alleviation of core symptoms within 2 h of a single low-dose intravenous infusion of ketamine with effects lasting up to 2 weeks. The rapidity of ketamine action implies that major symptoms of depression can be alleviated without substantial structural plasticity or circuit rewiring. Therefore, the ability of ketamine to exert a rapid effect provides a unique opportunity to elucidate the types of acute synaptic plasticity changes that can be recruited to counter depression symptoms.

Original languageEnglish (US)
Pages (from-to)35-39
Number of pages5
JournalCurrent Opinion in Pharmacology
Volume20
DOIs
StatePublished - 2015

Fingerprint

Ketamine
Antidepressive Agents
Depression
D-Aspartic Acid
Neuronal Plasticity
Aptitude
Major Depressive Disorder
Intravenous Infusions

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

How does ketamine elicit a rapid antidepressant response? / Kavalali, Ege T; Monteggia, Lisa M.

In: Current Opinion in Pharmacology, Vol. 20, 2015, p. 35-39.

Research output: Contribution to journalArticle

@article{b9805f7c0c634da2a129209329f14d4d,
title = "How does ketamine elicit a rapid antidepressant response?",
abstract = "A single sub-psychotomimetic dose of ketamine, an ionotropic glutamatergic n-methyl-D-aspartate (NMDA) receptor antagonist, produces a fast-acting antidepressant response in patients suffering from major depressive disorder. Depressed patients report alleviation of core symptoms within 2 h of a single low-dose intravenous infusion of ketamine with effects lasting up to 2 weeks. The rapidity of ketamine action implies that major symptoms of depression can be alleviated without substantial structural plasticity or circuit rewiring. Therefore, the ability of ketamine to exert a rapid effect provides a unique opportunity to elucidate the types of acute synaptic plasticity changes that can be recruited to counter depression symptoms.",
author = "Kavalali, {Ege T} and Monteggia, {Lisa M}",
year = "2015",
doi = "10.1016/j.coph.2014.11.005",
language = "English (US)",
volume = "20",
pages = "35--39",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - How does ketamine elicit a rapid antidepressant response?

AU - Kavalali, Ege T

AU - Monteggia, Lisa M

PY - 2015

Y1 - 2015

N2 - A single sub-psychotomimetic dose of ketamine, an ionotropic glutamatergic n-methyl-D-aspartate (NMDA) receptor antagonist, produces a fast-acting antidepressant response in patients suffering from major depressive disorder. Depressed patients report alleviation of core symptoms within 2 h of a single low-dose intravenous infusion of ketamine with effects lasting up to 2 weeks. The rapidity of ketamine action implies that major symptoms of depression can be alleviated without substantial structural plasticity or circuit rewiring. Therefore, the ability of ketamine to exert a rapid effect provides a unique opportunity to elucidate the types of acute synaptic plasticity changes that can be recruited to counter depression symptoms.

AB - A single sub-psychotomimetic dose of ketamine, an ionotropic glutamatergic n-methyl-D-aspartate (NMDA) receptor antagonist, produces a fast-acting antidepressant response in patients suffering from major depressive disorder. Depressed patients report alleviation of core symptoms within 2 h of a single low-dose intravenous infusion of ketamine with effects lasting up to 2 weeks. The rapidity of ketamine action implies that major symptoms of depression can be alleviated without substantial structural plasticity or circuit rewiring. Therefore, the ability of ketamine to exert a rapid effect provides a unique opportunity to elucidate the types of acute synaptic plasticity changes that can be recruited to counter depression symptoms.

UR - http://www.scopus.com/inward/record.url?scp=84912075332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912075332&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2014.11.005

DO - 10.1016/j.coph.2014.11.005

M3 - Article

VL - 20

SP - 35

EP - 39

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -